COMMUNIQUÉS West-GlobeNewswire

Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
01/06/2019
Data provides further evidence that GoCAR-T ® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received lymphodepletion with [...]
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
01/06/2019
Encouraging early signs of clinical efficacy Well tolerated with favorable safety profile in heavily pre-treated patient population CAMBRIDGE, Mass., June 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq [...]
CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
01/06/2019
- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif., June 01, 2019 (GLOBE NEWSWIRE) -- CytomX [...]
BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting
01/06/2019
CAMBRIDGE, Mass. and BEIJING, China, June 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting
01/06/2019
Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate ( [...]
Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
01/06/2019
SOUTH SAN FRANCISCO, Calif., June 01, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019
01/06/2019
Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of Viaskin ® Peanut DBV Technologies (Euronext: DBV – [...]
DBV Technologies : présentation de données sur l’immunothérapie épicutanée au congrès du EAACI 2019
01/06/2019
Montrouge, France, le 1 juin (14 h 00 CET) 2019 DBV Technologies : présentation de données sur l’immunothérapie épicutanée au congrès du EAACI 2019 Les données présentées mettent en évidence les avantages potentiels à [...]
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
01/06/2019
Conquer Cancer Foundation/ Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania Lugano, Switzerland, June [...]
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
01/06/2019
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for women who received Kisqali [...]
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting
01/06/2019
Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting Clinical trial initiated in February 2019 in the U.S., MD Anderson Cancer Center and Sarah [...]
Biocartis Group NV: Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies
01/06/2019
PRESS RELEASE : 1 June 2019, 07:00 CEST Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies Mechelen, Belgium, 1 June 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an [...]
Blissco Announces Q4 2019 Financial Results
01/06/2019
Not for distribution in the U.S. or to U.S. Newswires VANCOUVER, British Columbia, May 31, 2019 (GLOBE NEWSWIRE) -- Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA:GQ4B), (“Blissco” or the “Company”) is a [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2019
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019, that were previously [...]
Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/05/2019
SOUTH SAN FRANCISCO, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent [...]
Eve & Co Announces Appointment of Ivan Ross Vrána as VP Government Relations and Business Development
31/05/2019
TORONTO, May 31, 2019 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSXV: EVE; OTCQB: EEVVF) is pleased to announce that Ivan Ross Vrána has been appointed as a Vice President and will [...]
Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress
31/05/2019
Investor News no. 03/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 May 2019 Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress Veloxis Pharmaceuticals (OMX: VELO) [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/05/2019
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019
31/05/2019
MORRISVILLE, N.C., May 31, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN) today announced that it will hold its 2019 Annual Meeting of Stockholders on Wednesday, July 31, at 9:30 am [...]

Pages